Unknown

Dataset Information

0

Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue.

ABSTRACT:

SUBMITTER: Karris MY 

PROVIDER: S-EPMC4867124 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue.

Karris Maile Y MY   Jain Sonia S   Bowman Vi Q VQ   Rieg Gunter G   Goicoechea Miguel M   Dube Michael P MP   Kerkar Shubha S   Kemper Carol C   Diamond Catherine C   Sun Xiaoying X   Daar Eric S ES   Haubrich Richard H RH   Morris Sheldon S  

Journal of acquired immune deficiency syndromes (1999) 20160601 2

Similar Datasets

Unknown Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.
| S-EPMC2739977 | biostudies-literature
Unknown Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection.
| S-EPMC3572727 | biostudies-literature
Unknown Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature.
| S-EPMC3874614 | biostudies-literature
Unknown Cost-Effectiveness of Three Alternative Boosted Protease Inhibitor-Based Second-Line Regimens in HIV-Infected Patients in West and Central Africa.
| S-EPMC7018873 | biostudies-literature
Unknown Abacavir/lamivudine versus tenofovir/emtricitabine in virologically suppressed patients switching from ritonavir-boosted protease inhibitors to raltegravir.
| S-EPMC3552169 | biostudies-literature
Unknown Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials.
| S-EPMC6276924 | biostudies-literature
Unknown Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).
| S-EPMC3515052 | biostudies-literature
Unknown A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study.
| S-EPMC6352870 | biostudies-literature
Unknown Reduction of the HIV protease inhibitor-induced ER stress and inflammatory response by raltegravir in macrophages.
| S-EPMC3953206 | biostudies-literature
Unknown Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks.
| S-EPMC4335094 | biostudies-literature